BioAge is a biotechnology company focused on developing therapies to extend human healthspan and treat age-related diseases. Their primary goal is to help people live healthier, longer lives by delaying or reversing the aging process. To achieve this, BioAge uses various approaches, including biomarker discovery, drug discovery and development, and collaborations and partnerships. NLRP3 is a critical component of the inflammasome, a protein complex that assembles in response to infection and tissue damage and results in inflammation needed to promote healing. However, chronic inflammasome activation leads to pathologic inflammation that drives a vast number of immunologic and fibrotic disorders. Analysis of BioAge’s proprietary longitudinal human aging cohorts revealed that NLRP3 levels rise with age are associated with all-cause mortality. BioAge has discovered a family of chemically novel NLRP3 inhibitors. We are developing two compounds in parallel–one that enters the central nervous system, and the other that is topically delivered to the eye–to optimize our ability to address the many age-related diseases driven by chronic inflammasome activation.